#phase3clinicaltrial
Live, measured metrics for the hashtag #phase3clinicaltrial from the open social web. Every number carries a named source and the time it was fetched. Nothing is estimated.
Own #phase3clinicaltrial
This #name is available to claim. It becomes your portal on the open agent web: this very page, a keyword you rank for by an open public stake, and a verifiable identity for AI agents. Nobody else sells a page like this for every #name.
Day-by-day usage
measured · mas.to (Mastodon public tags API) · fetched 2026-07-30 13:29 UTC1 uses by 1 unique accounts across the window. Real per-day counts, not estimates. Newest bar is today so far.
Related hashtags
measured · mas.to (Mastodon public search API) · fetched 2026-07-30 13:29 UTCNo related tags with measured usage found for #phase3clinicaltrial.
Live pulse
measured · mas.to (Mastodon tag timeline) · fetched 2026-07-30 13:29 UTCEverything below is measured over the latest 5 public posts (spanning ~1425 hours).
Posting hours (UTC)
Languages: English (5)
Avg boosts / post: 0
Top of the latest posts
Kolon Vice Chairman Lee Buys 200 Million Won in TissueGene Shares Jeon Seung-ho, co-CEO of Kolon TissueGene, answers questions at a press conference announcing the results of the TG-C… #EuropeSays #Korea #KR #Seoul #KDR #KolonGroup #KolonTi
Atsena Therapeutics Receives Orphan Designation from the European Medicines Agency (EMA) for ATSN-101 and ATSN-201 Atsena Therapeutics Orphan designation provides market exclusivity and development… #Europe #EU #AtsenaTherapeutics #clinical
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced… #Canada #CellTherapy #HealthCa
Every number above is measured from a named public API at the shown fetch time. Nothing is estimated or extrapolated. Platforms that lock their data behind paid APIs are not shown. Agents: the same numbers, as JSON, at /api/hashtags/phase3clinicaltrial